TCM
BIO icon

Teza Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Teza Capital Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-400
Closed -$258K – 365
2021
Q2 		$258K Sell
400
-518
-56% -$315K 0.04% 459
2021
Q1 		$524K Buy
+918
New +$544K 0.1% 263
2020
Q1 		– Sell
-1,249
Closed -$462K – 161
2019
Q4 		$462K Buy
+1,249
New +$440K 0.13% 288
2019
Q3 		– Sell
-2,104
Closed -$658K – 500
2019
Q2 		$658K Buy
+2,104
New +$630K 0.39% 80

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Teza Capital Management's BIO Position: Q3 2021 in Review

Teza Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2021, closing a stake of 400 shares — an estimated $258K sold.

Teza Capital Management first reported a position in BIO in Q2 2019 and held it in 4 quarters. The position peaked at $658K in Q2 2019. 507 funds tracked by Wall St. Rank hold BIO as of Q3 2021.

  • Teza Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q3 2021 after selling out during the quarter.
  • Teza Capital Management sold 400 Bio-Rad Laboratories Class A shares in Q3 2021, an estimated $258K.
  • Teza Capital Management first reported a position in Bio-Rad Laboratories Class A in Q2 2019 and held it in 4 quarters.
  • Teza Capital Management's Bio-Rad Laboratories Class A position peaked at $658K in Q2 2019.
  • 507 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2021.

Based on Teza Capital Management's 13F filing for Q3 2021, filed 10 Nov 2021.